Research Study for Patients With Metastatic Renal Cell Carcinoma

Stopped early · Phase 2 · Has a placebo group

Conditions studied: Carcinoma, Renal Cell

In brief

This study has been designed to study patients diagnosed with advanced renal cell cancer with the primary tumor in place.

Key facts

Study ID

NCT00110344

Run by

Bayer

People needed

1

Starts

2005-11-01

Expected to finish

2006-06-01

Last updated by the study team

2013-10-11

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Life expectancy of at least 12 weeks
• Clinical, radiographic, or pathologic diagnosis of metastatic renal cell carcinoma (RCC). All renal cell histologies are allowed- Acceptable surgical risk in the judgment of the study investigator and consulting urological surgeon
• At least one uni-dimensional measurable lesion outside the planned nephrectomy specimen
• Patients who have an ECOG performance status of 0 or 1 Exclusion Criteria:
• History of bleeding diathesis or unexpected surgical bleeding- Patients currently receiving treatment with or having a requirement for therapeutic anticoagulation
• Prior therapy for RCC. Palliative radiation therapy for painful or unstable bone metastases is permitted provided that there is measurable metastatic disease outside the radiation field
• Known history of HIV infection- Symptomatic metastatic brain or meningeal tumors, unless the patient is > 6 months from definitive therapy, has a CT or MRI scan within 6 weeks of study entry negative for brain metastases and is clinically stable with respect to the tumor at the time of study entry

Where it is running

• Study site — Boston, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.